biliary atresia (ba) is a progressive fibro-obliterative cholangiopathy of unclear etiology affecting varying degrees of both extra-and intrahepatic biliary tree resulting in obstructive bile flow and cholestasis in neonates. the diagnostic work-up is designed to diagnose or rule out ba without any unnecessary delay. Kasai portoenterostomy is a palliative operation performed to establish bile drainage from microscopic bile ductules that remain in the porta hepatis. it is advantageous to perform portoenterostomy as early after birth as possible for better chances of success. actuarial native liver 5-year survival rates range from 30% to 60% after portoenterostomy, and about 20% of all patients undergoing Kasai portoenterostomy during infancy survive into adulthood with their native liver. Portoenterostomy remains as the first line operative treatment in ba while liver transplantation serves as a salvage treatment when portoenterostomy fails or liver function gradually deteriorates after initially successful establishment of bile flow.
(BASM) syndrome. In the remaining 80% of cases BA occurs in isolation without any associated disorders.
BA is classified based on the level of extrahepatic obstruction of the biliary tree (1). In type 1 BA (about 5%) the biliary tract is obstructed at the level of the common bile duct. In type 2 (about 2%), obstruction occurs at the level of the common hepatic duct. In type 3 (> 90%) BA, the most proximal part of the extrahepatic biliary tract in the porta hepatis is obstructed and fibrotic without any macroscopic remnants of the hepatic ducts. Additional cystic dilatation of the extrahepatic bile duct remnants may be present.
Even in the type 3 BA microscopic residual bile ductules of variable size remain in continuity with the intrahepatic biliary tree. Kasai portoenterostomy, initially described in 1959, is a palliative operation performed to establish bile drainage from these microscopic residual ductules (4). In Kasai portoenterostomy the microscopic bile ductules in the porta hepatis are exposed and drained via a small intestinal conduit in order to establish bile flow. In general, it is advantageous to perform portoenterostomy as early after birth as possible for better chances of success (5).
IntroDUCtIon
BA is a progressive fibro-obliterative cholangiopathy affecting varying degrees of both extra-and intrahepatic biliary tree resulting in obstructive bile flow, cholestasis and icterus in neonates (1, 2) . BA is solely a disease of infants and does not present after the neonatal period. It is a rare disease with an incidence of 1:15000-19000 live births in the Western World, whereas in Asia the incidence is clearly higher (3). Without treatment progressive hepatic fibrosis leads to cirrhosis, portal hypertension, liver failure and death by the age of 2 years (1, 2). Around 10-20% of cases are associated with other congenital disorders, most commonly biliary atresia splenic malformation Unsuccessful portoenterostomy with failure to establish sufficient bile flow is an indication to liver transplantation (Lt) . BA is the most common indication for Lt among children (6) . About 75% of Lts in children younger than 2 years are performed for patients with failed Kasai operation.
PAtHoPHySIoLogy the pathogenesis of BA is unknown. It is likely to be multifactorial and environmental and genetic factors may interact in the process of development of obstructive cholangiopathy (1, 7). Patients with a congenital form of BA have a constellation of anomalies that is labelled BASM syndrome. these patients (10-20% in the Western World) are more often female and they have variable combinations of associated malformations including asplenia/polysplenia, situs inversus, preduodenal portal vein, absent inferior vena cava, intestinal malrotation, cardiac malformations and pancreatic malformations. However, genetic aetiology has not been proven in these patients. there are mutations in the InVS gene that are associated with BASM phenotype in experimental animals but not in humans (1, 8) .
Viral causes for non-syndromic acquired BA, which constitutes over 80% of cases have been extensively studied in animal models (2). newborn mice, inoculated with reovirus, cytomegalovirus or rotavirus, develop jaundice and severe damage of the biliary tree similar to findings in human BA (9-11). However, in humans serological studies have shown contradictory results. In some studies PCr analysis from human liver tissue with BA have shown viral rnA or DnA, others have not been able to confirm this (12) (13) .
Inflammatory response in liver tissue is pronounced in patients with BA. there is a periductal infiltrate of mononuclear cells, amplification of HLA-Dr expression on biliary epithelium and enhanced expression of adhesion molecules (7). Abnormal expression of soluble inflammatory cytokines and adhesion molecules can be found also in the circulation of the patients with BA several months after successful portoenterostomy (14). It appears that lymphocyte-mediated inflammation mediates the biliary tract damage in BA. It is possible that perinatal exposure of hepatotropic viruses play a role in triggering this autoimmune inflammatory sequence in a genetic susceptible individual (1).
DIAgnoSIS
Most neonates with BA present shortly after birth with prolonged jaundice, acholic stools and dark urine. Some infants may present with bleeding and vitamin K deficiency associated coagulopathy due to malabsorption particularly if neonatal administration of vitamin K has been omitted. Usually infants presenting within three months from birth do not show clinical findings of cirrhosis and portal hypertension such as ascites, splenomegaly or esophageal varices. typical laboratory findings include moderate to high conjugated hyperbilirubinemia, clearly elevated glutamyl transferase, mildly to moderately elevated serum aminotransferases and variably preserved serum markers of hepatic synthetic function. BA should be ruled out or identified in all infants with prolonged neonatal jaundice beyond two weeks of age and conjugated hyperbilirubinemia. thus, all newborns remaining jaundiced after 14 days should be investigated for liver disease initially with measurement of serum conjugated bilirubin. In Finland further assessment without a delay is recommended for those with conjugated bilirubin over 20 µmol/l (1.2 g/dl) or over 20% of the total bilirubin (15). Harmless and much more common breast-milk jaundice increases serum concentration of unconjugated instead of conjugated.
Because early diagnosis of BA is advantageous, the diagnostic work-up is designed to diagnose or rule out BA without any unnecessary delay. In addition to clinical picture and laboratory tests, diagnostic modalities include abdominal ultrasound, radioisotope excretion scan, liver histology, endoscopic retrograde cholangiography, and finally intraoperative cholangiography and operative findings. Different combinations of these investigations are employed depending on the patient's clinical picture. Differential diagnosis of neonatal cholestasis is broad and includes various structural, infectious, metabolic, genetic and toxic conditions (2, 15). Further, often laborious, investigations for these disorders are continued once BA has been ruled out (table 1) .
typical findings of BA in ultrasound include absent, hypoplastic or contracted gallbladder, although a significant portion of patients have a normal gallbladder. Furthermore, the choledochal duct may rarely be visible despite more proximal atresia of the biliary tract. Hyperechogenic liver hilum, known as the triangular cord sign, has been reported to be a common and specific but operator-dependent finding in BA (16). Abdominal ultrasound is also useful in order to rule out choledochal cyst, which should not be confused with a cystic type of BA.
A radioisotope excretion scan typically show good hepatic uptake combined with absent or clearly reduced secretion of an isotope within 24 hours. these findings are not specific for BA, and reduced hepatic excretion may be observed in other conditions resulting in intrahepatic cholestasis such as Alagille syndrome associated with hypoplastic biliary tree. normal hepatic excretion of the isotope rules BA out with a great certainty.
Liver histology is obtained by percutaneous ultrasound guided biopsy. typical histological findings in BA include varying degrees of portal fibrosis, bile duct proliferation, cholestasis and inflammation. the degree of liver fibrosis varies from mild portal tract fibrosis to bridging fibrosis and cirrhosis. occasionally, giant cell transformation is observed, impeding the differential diagnosis between BA and neonatal hepatitis, which can be especially difficult early in the course of the disease due to dynamic nature of liver histology in BA. our practice is to use endoscopic retrograde cholangiography selectively mainly when findings in radioisotope excretion scan and liver biopsy are uncertain (17). Intraoperative cholangiography is performed before portoenterostomy if there is any doubt of the diagnosis at the time of operation.
FIrSt LInE oPErAtIVE trEAtMEnt
Kasai portoenterostomy remains as the first line operative treatment in BA while Lt serves as a salvage treatment when portoenterostomy fails or liver function gradually deteriorates after initially successful establishment of bile flow. In many children portoenterostomy provides adequate bile flow and clearance of jaundice with a decrease of bilirubin levels within normal range resulting in prolonged survival with their native liver. Although the majority of children with BA eventually require Lt, postponing transplantation into later childhood, adolescence or even in adulthood may be advantageous in several ways. With the growth of the child technical demands of Lt decrease thereby reducing surgical complications and availability of potential liver graft donors increases. In addition, exposure to side-effects of life-long immunosuppressive therapy is shortened.
Biliary obstruction in untreated BA is associated with progressive cholestasis, liver fibrosis and cirrhosis. Early surgery before development of extended liver damage is more likely to result in improved outcomes, although no clear-cut age limit exists (5). Experience of the center is also an important predictor of outcome (18) We use a generous transverse upper abdominal incision and mobilize the liver fully from its ligaments for optimal exposure. the abdominal cavity is carefully inspected for associated anomalies. If any doubt of the diagnosis exists a cholangiography through the gallbladder in performed. there is usually a fibrotic connection from the gallbladder to the porta hepatis representing the destructed common hepatic duct. this fibrotic structure is carefully freed from the adjoining vessels and followed up to the porta hepatis. the porta hepatis is cleared between hepatic arteries and behind the portal bifurcation, which requires its mobilization from the liver and division of small branches to the liver segment I. A bridge of liver tissue between segments III and V over the site where left side vessels enter the liver parenchyma is divided when present for optimal ex-posure. the fibrotic portal plate is incised sharply parallel to and at level of the liver capsule. A retrocolic 40 cm jejunal roux limb is anastomosed to the cleared porta hepatis. our practice is to avoid dissection distal to the gall bladder in order to avoid unnecessary adhesions in later Lt. the abdomen is drained for 5 days mainly for occasional excretion of ascites.
CoMPLICAtIonS the most common surgical complications after successful portoenterostomy include ascending cholangitis and portal hypertension with or without esophageal varices (19) . Both of these complications may occur despite effective clearance of jaundice and serum bilirubin within normal range. Because of ongoing cirrhotic change of the liver, there is a small risk of hepatic malignancy necessitating regular follow-up of all patients.
Cholangitis occur most often early after portoenterostomy and may present with abdominal pain, fever and elevated inflammatory parameters associated with variable increase in serum bilirubin and aminotransferases. Usually they respond well to intravenous antibiotics such as ceftriaxon. recurrent cholangitis may be associated with intrahepatic cystic dilatations known as biliary lakes, which are readily appar- (20). Portal hypertension may develop rapidly especially after failed portoenterostomy resulting in ascites formation, splenomegaly and esophageal varices. A significant proportion of esophageal varices in BA patients bleed. Variceal bleeding after failed Kasai with compromised liver function may result in rapid deterioration of general condition. We perform yearly surveillance upper endoscopies for esophageal varices and give prophylactic sclerotherapy once varices are encountered. overall majority of the patients develop esophageal varices along the course of their disease.
ADJUVAnt MEDICAL tHErAPy
Adjuvant medical therapy is commonly used after Kasai portoenterostomy. the rationale of adjuvant medications include prevention of postoperative cholangitis, stimulation of bile flow and reducing hepatic inflammation and progressive fibrosis associated with BA.
Most centers use oral antibiotic prophylaxis in order to decrease frequency of cholangitis. Variable antimicrobial preparations (amoxicillin, cefalexin, trimethoprim) and their combinations are used while there are little published data to support one antibiotic over another. Many programs employ corticosteroids for variable period of time after portoenterostomy. In addition to their anti-inflammatory and immunomodulatory properties, steroids enhance bile salt dependent bile flow. one randomized controlled trial on postoperative steroid treatment with oral prednisolone from day 7 to day 28 found no significant effect on native liver survival, although patients in the steroid arm had lower serum bilirubin at six months after the operation (21). oral ursodeoxycholic acid is also commonly used with variable dosage in order to stimulate bile flow and also for its possible liver protective effects. Ursodeoxycholic acid has been shown to be beneficial among adults with primary biliary cirrhosis. there are no randomized controlled studies on ursodeoxycholic treatment in BA. However, one prospective study using discontinuation/reintroduction method clearly indicated its positive effect after successful Kasai portoenterostomy (22). our protocol includes dexamethasone, ursodeoxycholic acid, phenobarbital and sulfamethoxazoletrimethoprim of which ursodeoxycholic acid and sulfamethoxazole-trimethoprim are continued after discharge (23).
LIVEr trAnSPLAntAtIon
BA is the most common indication for Lt in children. Unsuccessful Kasai portoenterostomy and refractory growth failure are the most common indications for Lt among children with BA. there is a large number of other indications related to advanced or end stage liver disease, including refractory ascites, variceal bleeding, recurrent cholangitis, progressive cholestasis, intractable pruritus, deterioration of hepatic syn-thetic function and hepatopulmonary syndrome etc (2, 6) . A significant proportion of children with failed portoenterostomy are transplanted after development of these complications. Most patients with BA require transplantation during infancy or the first years of life. Small recipient size obligates frequent employment of technical variant grafts, mainly segments II and III from adult donors. Severe associated, mainly cardiac, malformations may preclude Lt from treatment of BA.
Lt among children with BA and previous portoenterostomy is often characterized by small recipient size, technical challenges of hepatic arterial anastomosis and biliary reconstruction, limited intra-abdominal space and adhesions (6). About 10% of recipients with BA have significant vascular and/or intestinal malformations due to BASM (see above). Careful intra-abdominal positioning of a technical variant graft is essential in order to avoid twisting of vascular structures.
Intra-abdominal adhesions especially after failed portoenterostomy and portal hypertension may predispose to intestinal perforations during dissection (6). Hepatic arterial complications occur in up to 15% of children undergoing Lt for BA (6). Modern microsurgical techniques have decreased the complication rate substantially. Although the portal vein is often hypoplastic portal venous complications appear to occur in similar frequency (8%) in children with BA than in those transplanted for other indications (24, 25) . With whole liver grafts overall rate of portal vein thrombosis is clearly less, about 4% (24). the overall incidence of biliary complications is relatively high (25%) mainly associated with use of technical variant grafts (6, 24) . nearly all biliary complications can be successfully treated with varying combination of drainage, interventional radiological procedures and surgery without need for retransplantation. Staged wound closure is often mandatory in order to avoid increased pressure on the graft and resulting vascular compromise and complications. this can be managed by initial skin closure without fascial closure or by temporary use of prosthetic material. According to our experience, reoperations are common (50%) after Lt for BA and they are performed most commonly after transplantation of a technical variant graft for postoperative hemorrhage. oUtCoMES oF SUrgEry For BA outcomes of surgery for BA can be assessed by the rate of clearance of jaundice (serum bilirubin within normal range) after portoenterostomy, by survival with native liver and by overall survival (table 2) . Portoenterostomy may be considered successful if serum bilirubin normalizes and jaundice is cleared after operation. In general, over half of the patients normalize their bilirubin after Kasai portoenterostomy within six months and actuarial native liver 5-year survival rates ranging from 30% to 60% have been reported (15). In Helsinki between 1991 and 2008 clearance of jaundice occurred in 70% of cases and 5-year native liver survival rate was 59% (26).
Currently, about 20% of all patients undergoing Kasai portoenterostomy during infancy survive into adulthood with their native liver (2, 15). Serum bilirubin after portoenterostomy is the strongest predictor of outcome. normal serum bilirubin level within few months after portoenterostomy predicts favorable long-term outcome (1, 2).
As already mentioned, increased age at surgery progressively worsens outcomes of portoenterostomy in terms of native liver survival (5). other factors affecting the outcome include the extent of liver damage and experience of the center. the extent of liver fibrosis at the time of portoenterostomy appears to be a strong negative predictor of outcome (27) . Five or more cases per year were associated with improved outcomes in the UK (18). In Finland centralization has clearly improved nationwide and institutional outcomes of BA in terms of clearance of jaundice and native liver survival, although the age at portoenterostomy has remained unchanged (28).
BA is the most common reason for Lt and may be the common end point for all children with BA. Excellent outcomes of Lt among children in general enable high overall survival of patients with BA. A relatively recent national study reported 1-year patient and graft survival rates of 92% and 84% for children undergoing Lt for BA (29). Among patients transplanted for BA, 5-year patient and graft survival rates range between 85-98% and 71-98%, respectively (6). Complex vascular anomalies present among recipients with BASM are associated with decreased patient survival following Lt in relation to BA patients without associated malformations (25) 
